Browse our anti-LGALS1 (LGALS1) Antibodies

Human Lectin, Galactoside-Binding, Soluble, 1 (LGALS1) interaction partners

1. Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of androgen receptor (AR) and Akt signaling. LLS30 targets Gal-1 as an allosteric inhibitor and decreases Gal-1-binding affinity to its binding partners. LLS30 showed in vivo efficacy in both AR-positive and AR-negative xenograft models.

2. Study found that variations in the gene coding for the cytokine Galectin-1 may provide a prognostic biomarker in glioblastoma.

3. Dysfunctional immunoregulation in liver allograft rejection patients can be partly attributed to reduced regulatory T-cell Gal1 expression and reduced responder T-cell CD7 expression.

4. our data show that Gal-1 modulates inflammatory responses in Sertoli cells by enhancing the pro-inflammatory activity of TNFalpha via stimulation of MAPK signalling.

5. Intestinal type of gastric cancer associated with connective tissue dysplasia is characterized by a high level of expression of galectin-1 and vimentin in the perifocal zone and TGF-beta in the tumor zone.

6. High LGALS1 expression is associated with the pathogenesis of age-related macular degeneration.

7. Gal-1 and Gal-3 through their binding partners may form a supramolecular structure at the cell surface of fibroblasts, immune cells, endothelial cells, and in the extracellular space that might influence the fibroblast morphology, adhesion, proliferation, migration, and survival as well as the inflammatory responses.

8. Increased Galectin-1 expression was found in neuroblastoma and it was further demonstrated that elevated tissue Galectin-1 expression was related to INSS stage, histology, bone marrow metastasis, and poor survival.

9. Galectin-1 and galectin-3 are overexpressed in renal cell carcinoma with different percentage in different subtypes

10. serum level of Gal-1 is a novel risk factor for both gestational hypertension and preeclampsia, specifically its expression at a low level in the second trimester and a high level after onset.

11. Silencing Gal-1 impaired invasiveness, and decreased S1PR1 expression and overexpression in gastric cancer can promote the expression of S1PR1and invasion of gastric cancer cells.

12. Association of galectin-1 expression with eosinophilic infiltration of the tumor tissue in stomach and colorectal cancer was detected.

13. Study shows that recombinant Galectin-1 (Gal-1) could promote the differentiation and invasion of Trophoblast stem cells (TSCs), suggesting that some of Ishikawa cells secretion increase the expression of Gal-1 in TSCs during implantation, which then induced trophoblast differentiation and invasion in vitro.

14. In conclusion, these findings suggest that the serum levels of Gal-1, Gal-3, and Gal-9 may be associated with large artery atherosclerotic stroke.

15. High LGALS1 expression is associated with fibrosis in chronic pancreatitis and pancreatic cancer.

16. Pancreatic stellate cells promote cancer proliferation, migration, and invasion via Gal1-driven pathways. Gene-expression analyses of pancreatic tumor cells exposed to Gal1 reveal modulation of multiple regulatory pathways involved in tumor progression.

17. Studies indicate tumor-derived galectin-1, galectin-3 and galectin-9 in various cancers and anticancer therapies that target these molecules [Review].

18. The expression level of galectin-1 affects survival in patients with glioblastoma multiforme treated with adjuvant radiotherapy

19. Results show that Galectin-1 teams up with Galectin-3 to induce inflammatory/pro-degradative gene signature in human chondrocytes affecting the progression of osteoarthritis. Also, Galectin-3 was found to induce a pro-degradative-inflammatory gene signature in human chondrocytes, teaming up with Galectin-1 in the pathogenesis of osteoarthritis.

20. We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. These results highlight a novel function of a human-used drug as a means of boosting the antitumor response

Pig (Porcine) Lectin, Galactoside-Binding, Soluble, 1 (LGALS1) interaction partners

1. Gal-1 may serve as an adhesion molecule to interact with both cells and laminins

2. Gal-1 is expressed in a wide range of porcine tissues, including striated muscle, liver, lung, brain, kidney, spleen, and intestine

3. LGALS1 was found widely expressed in all tissues and transient transfection indicated that galectin-1 locates both in cytoplasm and nucleus.

Cow (Bovine) Lectin, Galactoside-Binding, Soluble, 1 (LGALS1) interaction partners

1. Data suggest that galectin-1 and VEGFR-2 are expressed at mid-luteal stages in luteal cells of corpus luteum; galectin-1 binds directly to asparagine-linked glycans (N-glycans) on VEGFR-2 in luteal cells.

2. The relative abundance of PIBF, LGALS1, LGALS3, LGALS3BP, and LGALS9 mRNA would display a differential expression pattern in the endometrium.

3. The binding affinity and specificity of galectin-1 for eight different beta-galactosyl terminal disaccharides was studied using molecular-dynamics simulations.

Mouse (Murine) Lectin, Galactoside-Binding, Soluble, 1 (LGALS1) interaction partners

1. Study in a murine model of prostate cancer demonstrates that endogenous Gal-1 in lymphocytes modulates their proliferative rate and cytotoxic function in conditions of high extracellular Gal-1 concentration, mainly derived from tumor cells. In such conditions, the absence of Gal-1 in T lymphocytes potentiates anti-tumor immune responses, so GAL-1 acts as a negative regulator of anti-tumor immunity.

2. Loss of Lgals1 is associated with defective regulatory function of B cells.

3. High LGALS1 expression is associated with choroidal neovascularization and subretinal fibrosis mediated via epithelial-mesenchymal transition.

4. In summary, the authors concluded that glycosylation-dependent Gal-1/NRP-1 interactions activate TGF-beta and PDGF-like signaling to promote the migration and activation of hepatic stellate cells.

5. These findings suggest a potential role of galectin-1 in the differentiation of mouse trophoblast stem cells.

6. silencing the gene expression of Galectin1 ameliorates liver fibrosis.

7. Overexpression of galectin-1 inhibited the proliferation of T-cells by means of HSC activation, which reduced the inflammatory response by exerting immunosuppressive effects and furthermore enhanced immune tolerance and alleviated hepatic fibrosis in liver transplantation.

8. Gal-1 is a major driver of pancreatic cancer progression. Genetic deletion of Gal1 in a Kras-driven mouse model of pancreatic ductal adenocarcinoma results in a significant increase in survival through mechanisms involving decreased stroma activation, attenuated vascularization, and enhanced T cell infiltration leading to diminished metastasis rates.

9. This work identified Gal1, an endogenous immune regulatory lectin, as an integral component of the secretory granule machinery and unveil the unexpected function of this lectin in regulating CTL killing activity.

10. The results of this study showed that development of spinal axons as well as the locomotor abilities observed in adult mice are independent of Gal-1.

11. GAL-1 also enhanced the generation of neural crest cells from explanted neural tubes

12. this present study indicated that Gal-1 secreted from MSCs upregulated expression of Gal-1 and stimulated formation of tolerance immunophenotype on DCs, where the underlying mechanism was the regulation of the MAPK signaling pathway in DCs, thereby inhibiting the function of DCs

13. markedly increased brain Gal-1 and S-nitrosylated Gal-1 both in scrapie-infected rodents and human prion diseases.

14. Gal-1 can limit eosinophil recruitment to allergic airways and suppresses airway inflammation by inhibiting cell migration and promoting eosinophil apoptosis.

15. Gal1 protein is essential for efficient liver regeneration following partial hepatectomy through the regulation of liver inflammation, hepatic cell proliferation, and the control of lipid storage in the regenerating liver.

16. findings show that galectin-1 (Gal-1), an immunoregulatory lectin widely expressed in mucosal tissues, contributes to Y. enterocolitica pathogenicity by undermining protective antibacterial responses.

17. Gal-1 functions as an important regulator in RNV and offers a promising strategy for the treatment of RNV diseases, such as proliferative diabetic retinopathy and retinopathy of prematurity.

18. These findings demonstrate that galectin-1 is required for i.v. tolerance induction, likely via induction of tolerogenic DCs leading to enhanced development of Tr1 cells, Treg cells, and downregulation of proinflammatory responses.

19. this study shows that galectin-1 secreted by Sertoli cells plays a pivotal role in the differentiation of functionally tolerogenic dendritic cells

20. analysis of the effect of low-temperature plasma on the expression of galectin-1, -2, and -3 in the healing skin compared with those of electrocoagulation conducted with a high-frequency electrical coagulator

Horse (Equine) Lectin, Galactoside-Binding, Soluble, 1 (LGALS1) interaction partners

1. Equine bone marrow mesenchymal stromal cells constitutively express high levels of galectin-1 mRNA relative to other articular cell types, suggesting a possible mechanism for their intra-articular immunomodulatory properties.